Synergistic Potential of Kleo’s Anti­body Recruiting Molecule (ARM™) and Celularity’s Placental-Derived NK Cells to Be Evaluated in the Context of COVID-19 and Multiple Myeloma

New Haven, CT (Press Release) – Kleo Pharma­ceu­ticals, Inc., a lead­ing com­pany in the field of devel­op­ing next-gener­a­tion, fully syn­thet­ic bispecific com­pounds de­signed to emulate or en­hance the ac­­tiv­ity of bio­log­ics, and Celularity, Inc., a lead­ing de­vel­oper of allo­geneic, or “off-the-shelf”, natural killer (NK) cell ther­a­pies, to­day an­nounced a pre­clin­i­cal re­search col­lab­o­ration to rapidly ad­vance syn­­er­gis­tic com­bi­na­tions of each com­pany’s tech­nology plat­form as poten­tial treat­ments for COVID-19 and mul­ti­ple myeloma.

The col­lab­o­ration comes at an opportune time for both com­pa­nies. Earlier this year, Kleo re­ceived IND authori­za­tion from the U.S. Food and Drug Admin­istra­tion (FDA) …

Newton, MA (Press Release) – Karyo­pharm Thera­peutics Inc. (Nasdaq:KPTI) to­day an­nounced dosing of the first patient in a ran­dom­ized Phase 2 clin­i­cal study eval­u­ating low dose oral selinexor in hos­pi­talized patients with severe COVID-19. This global study is ex­pected to en­roll approx­i­mately 230 patients at clin­i­cal sites in the U.S., Europe, and Israel. Selinexor is an oral selective in­hib­i­tor of nuclear export (SINE) com­pound which blocks the cellular pro­tein XPO1 which is in­volve­d in both the rep­li­ca­tion of SARS-CoV-2, the virus that causes COVID-19, and in the in­flam­ma­tory re­sponse to the virus.

The …

• Company to Initiate a Global Randomized Clinical Trial to Treat Patients with COVID-19
• XPO1 Inhibitors have Previously Demonstrated Pre­clin­i­cal Activity Against Numerous Respiratory Viruses (Including SARS-CoV) and Asso­ci­ated Inflammation
• BOSTON sNDA Submission on Target for Q2 2020
• Management to Host Conference Call Today at 8:30 AM ET

Newton, MA (Press Release) – Karyo­pharm Thera­peutics Inc. (Nasdaq:KPTI) to­day announced plans to ini­ti­ate a global ran­dom­ized clin­i­cal trial for low dose oral selinexor in hos­pi­talized patients with severe COVID-19. Selinexor, mar­keted as XPOVIO®, is cur­rent approved at higher doses by the Food and Drug Admin­istra­tion (FDA) as a treat­ment for patients with re­lapsed or re­frac­tory multiple myeloma. Selinexor is an oral, selective in­hib­i­tor of nuclear export (SINE) com­pound which blocks the cellular pro­tein XPO1. In addi­tion to …

CYNK-001, the com­pany's allo­geneic, off-the-shelf, cryo­pre­served Natural Killer cell ther­apy to be used in Phase I/II study

Warren, NJ (Press Release) – Celularity Inc. ("Celularity" or the "Com­pany"), a clin­i­cal-stage com­pany devel­op­ing allo­geneic cel­lu­lar ther­a­pies from human pla­cen­tas, to­day an­nounced the U.S. Food and Drug Admin­istra­tion (FDA) has cleared the Com­pany's Inves­ti­ga­tional New Drug (IND) appli­ca­tion for the use of its pro­pri­e­tary CYNK-001 in adults with COVID-19. With this, Celularity will com­mence a Phase I/II clin­i­cal study in­clud­ing up to 86 patients with COVID-19. The Com­pany be­lieves CYNK-001 is the first immuno­therapy IND cleared by the FDA to treat COVID-19 infected adults.

"This IND rep­re­sents a sig­nif­i­cant step to­ward a po­ten­tial …

Coronavirus dis­ease 2019, or COVID‑19, has been all over the news here in Canada lately as the virus spreads to North America.

Fortunately, so far in Canada, the rate of infected and diag­nosed patients is still at a low level. In order to prevent the spread of COVID‑19, how­ever, large gather­ings have been cancelled.

The Juno's, Canada's annual music award cer­e­mony, were cancelled this month, and the National Hockey League (NHL) has suspended its season early. Even the Toronto Raptors, a mem­ber of the National Basketball Association (NBA), have suspended play …